Teva Pharmaceutical Industries Limited (NYSE:TEVA) went down by -1.33% from its latest closing price compared to the recent 1-year high of $11.44. The company’s stock price has collected -8.44% of loss in the last five trading sessions. The Wall Street Journal reported on 11/21/22 that Teva Pharmaceutical Names Richard Francis as CEO
Is It Worth Investing in Teva Pharmaceutical Industries Limited (NYSE :TEVA) Right Now?
Plus, the 36-month beta value for TEVA is at 1.20. Opinions of the stock are interesting as 2 analysts out of 13 who provided ratings for Teva Pharmaceutical Industries Limited declared the stock was a “buy,” while 1 rated the stock as “overweight,” 7 rated it as “hold,” and 3 as “sell.”
The average price from analysts is $10.11, which is -$0.41 below the current price. TEVA currently public float of 1.09B and currently shorts hold a 2.89% ratio of that float. Today, the average trading volume of TEVA was 9.72M shares.
TEVA’s Market Performance
TEVA stocks went down by -8.44% for the week, with a monthly jump of 21.47% and a quarterly performance of 29.00%, while its annual performance rate touched 17.76%. The volatility ratio for the week stands at 2.74% while the volatility levels for the past 30 days are set at 3.51% for Teva Pharmaceutical Industries Limited. The simple moving average for the period of the last 20 days is 3.63% for TEVA stocks with a simple moving average of 17.33% for the last 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Jefferies repeating the rating for TEVA by listing it as a “Hold.” The predicted price for TEVA in the upcoming period, according to Jefferies is $12 based on the research report published on January 19th of the current year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $10, previously predicting the price at $11. The rating they have provided for TEVA stocks is “Underweight” according to the report published on November 14th, 2022.
TEVA Trading at 11.65% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.04% of loss for the given period.
Volatility was left at 3.51%, however, over the last 30 days, the volatility rate increased by 2.74%, as shares surge +19.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.57% upper at present.
During the last 5 trading sessions, TEVA fell by -8.44%, which changed the moving average for the period of 200-days by +5.26% in comparison to the 20-day moving average, which settled at $10.13. In addition, Teva Pharmaceutical Industries Limited saw 14.14% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TEVA starting from Kalif Eliyahu Sharon, who sale 55,500 shares at the price of $10.07 back on Aug 22. After this action, Kalif Eliyahu Sharon now owns 9,376 shares of Teva Pharmaceutical Industries Limited, valued at $558,696 using the latest closing price.
Stark David Matthew, the Exec. VP Chief Legal Officer of Teva Pharmaceutical Industries Limited, sale 58,163 shares at $9.04 during a trade that took place back on Jul 28, which means that Stark David Matthew is holding 2,974 shares at $525,590 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- +19.36 for the present operating margin
- +47.10 for the gross margin
The net margin for Teva Pharmaceutical Industries Limited stands at +2.63. The total capital return value is set at 8.67, while invested capital returns managed to touch 1.30. Equity return is now at value -13.80, with -2.80 for asset returns.
Based on Teva Pharmaceutical Industries Limited (TEVA), the company’s capital structure generated 229.31 points at debt to equity in total, while total debt to capital is 69.63. Total debt to assets is 49.44, with long-term debt to equity ratio resting at 214.37. Finally, the long-term debt to capital ratio is 65.10.
When we switch over and look at the enterprise to sales, we see a ratio of 2.15, with the company’s debt to enterprise value settled at 0.74. The receivables turnover for the company is 3.55 and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.14.